AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2017 Earnings Presentation

34 slides from AMAG Pharmaceuticals's earnings presentation, May 2, 2017

  1. Slide 1: AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update

    AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update May 2, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, Make

  3. Slide 3: Q1-2017 Earnings Call Agenda

    Q1-2017 Earnings Call Agenda 3 Q1-2017 and Recent Highlights 1 6 Q&A 2 Commercial Overview 5 2017 Key Priorities and Closing Remarks 4 Financial Results and Guidance 3 Feraheme Broad Label Study Results

  4. Slide 4: Q1-2017 Highlights and Recent Events

    Q1-2017 Highlights and Recent Events 4  Filed sNDA with the FDA for Makena subcutaneous (sub-q) auto-injector  Increased Makena market share by 2% over Q4-2016 to 44%  Reported positive Feraheme data from Phase 3 label expansion study  Closed licensing transactions in the women’s health space fo

  5. Slide 5: Q1-2017 Financial Highlights

    Q1-2017 Financial Highlights 5 GAAP Product Revenue ($ M) $109.3 $139.5 Q1-2016 Q1-2017 +28% 1 Includes a one-time payment of $60 M to Palatin Technologies. 2 See slide 31 for reconciliations of GAAP to non-GAAP financial information. GAAP Operating Income ($ M) Non-GAAP Adj. EBITDA2 ($ M) $47.5 $57

  6. Slide 6: Further Expanding AMAG's Product Portfolio

    Further Expanding AMAG’s Product Portfolio 6 Pregnancy & Birth Wellness Post-Menopausal Health Feraheme Makena Velo Option Cord Blood Registry Used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) The only FDA-approved therapy to reduce recurrent

  7. Slide 7: Product Portfolio Commercial Overview

    Product Portfolio Commercial Overview Nik Grund Chief Commercial Officer

  8. Slide 8: Makena: Continued Growth

    Makena: Continued Growth 8 $65.0 $86.5 Q1-2016 Q1-2017 Makena Revenue ($M) M A T E R N A L H E A L T H : M A K E N A +33% 1 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market research data conducted by AMAG. 2 Based on 140,

  9. Slide 9: Makena: Increasing Underlying Demand

    Makena: Increasing Underlying Demand1 9 M A T E R N A L H E A L T H : M A K E N A 0 50 100 150 200 250 Q4-2015 Q1-2016 Makena Ex-factory Doses Makena Demand Doses 0 50 100 150 200 250 Q4-2016 Q1-2017 (thousands) (thousands) 1 Based on actual dispensing (shipments to physician/hospital/patients) data

  10. Slide 10: Makena 2017 Growth Drivers

    M A T E R N A L H E A L T H : M A K E N A 10 Continue share gains from compounders and grow Makena @Home administration 1 Expand use in late preterm birth segment 2 Launch subcutaneous auto-injector1 3 Makena 2017 Growth Drivers 1 If regulatory approval is received.

  11. Slide 11: CBR: Attractive Recurring Revenue Stream Return to Growth

    11 $19.5 $26.9 Q1-2016 Q1-2017 $28.1 $28.3 Q1-2016 Q1-2017 GAAP CBR Revenue ($M) Non-GAAP CBR Revenue1 ($M) CBR: Attractive Recurring Revenue Stream Return to Growth M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y 1 Non-GAAP CBR revenue includes purchase accounting adjustments relate

  12. Slide 12: CBR 2017 Growth Drivers

    CBR 2017 Growth Drivers 12 Differentiate CBR’s offerings – Highlight cord tissue storage offering – Enhance product offerings 1 Build value proposition on storing newborn stem cells – Harmonizing annual storage price across client base 2 Leverage advancements in stem cell research with OB/GYN’s and

  13. Slide 13: Advancements in Stem Cell Research

    Advancements in Stem Cell Research 13 M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y

  14. Slide 14: Dyspareunia: Sizable Untapped Treatment Market

    Affected, but not yet seeking treatment Utilizing OTC treatments Previous estrogen therapy users Dyspareunia: Sizable Untapped Treatment Market 14 1 Based on IMS SMART Tool NSP and NPA data. 2 IMS Health Plan Claims (April 2008-11). 3 AMAG estimates based on: a) Wysocki et al. Management of Vaginal

  15. Slide 15: Intrarosa: Investing Today for a Significant Tomorrow

     Leveraging existing strengths: – Medical affairs – Market access team – Analytics team – Digital consumer platform  Preparing for Launch – In process of hiring a new approximately 150-person women’s health commercial team – Conducting market research, including product positioning and concept tes

  16. Slide 16: Feraheme: Differentiated Product, Expect Future Growth

    Feraheme: Differentiated Product, Expect Future Growth 16 $24.2 $25.9 Q1-2016 Q1-2017 Feraheme Revenue1 ($M) +7% H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 2017 Growth Drivers  Continued growth in key segments  Pull through recent GPO access wins  Optimize net revenue per gram  Prep

  17. Slide 17: Feraheme Broad Label Study Results

    Feraheme Broad Label Study Results Julie Krop, MD Chief Medical Officer

  18. Slide 18: Feraheme Phase 3 Label Expansion Study Overview

    Feraheme Phase 3 Label Expansion Study Overview Sample size • 1,997 patients randomized in a 1:1 ratio Dosing Regimen • 2 doses of Feraheme (1.02g)* or Injectafer (1.5g)*, dosed 7 days apart Key entry criteria • Subjects with IDA and in whom intravenous iron treatment is indicated and have failed pr

  19. Slide 19: Achieved Both Primary and Secondary Safety Endpoints

    Achieved Both Primary and Secondary Safety Endpoints Composite Primary Endpoint Feraheme IV (1.02 g) (n=997) n (%) Injectafer IV (1.5 g) (n=1,000) n (%) Rate Difference (%) (95% CI) Non-inferiority p-value Incidence of moderate-to-severe hypersensitivity reactions (including anaphylaxis)* and/or mod

  20. Slide 20: Achieved Both Secondary Efficacy Endpoints

    Achieved Both Secondary Efficacy Endpoints Composite Secondary Efficacy Endpoints Feraheme IV (1.02 g) (n=997) LS Mean (SE) Injectafer IV (1.5 g) (n=1,000) LS Mean (SE) Treatment Difference (%) (95% CI) p-value Mean change in hemoglobin (g/dL) per gram of iron administered* 1.36 (0.03) 1.09 (0.03) 0

  21. Slide 21: Broad IDA Label Would Double Market Opportunity

    Broad IDA Label Would Double Market Opportunity1 21 Feraheme ~26% Other IV irons ~74% IDA IV Iron Market (non-dialysis) Market Opportunity with Broad IDA indication1 ~$700M / year (non-dialysis)2 IDA IDA-CKD IDA-CKD IDA 4.5 million Americans diagnosed with IDA3 1.5 million in women’s health 1 If reg

  22. Slide 22: Financial Overview

    Financial Overview Ted Myles Chief Financial Officer

  23. Slide 23: Continued Revenue Growth and Portfolio Investment

    23 $109.3 $139.5 ($40.0) $7.4 Q1-2016 Q1-2017 +28% Makena revenue CBR revenue Feraheme/MuGard revenue GAAP Operating income (loss) / non-GAAP Adj. EBITDA GAAP Financials ($M) $117.9 $140.8 $47.5 $57.6 Q1-2016 Q1-2017 +19% Non-GAAP Financials ($M) 1 Non-GAAP CBR revenue includes purchase accounting a

  24. Slide 24: Strong Cash Flow Generation

    Strong Cash Flow Generation ($M) 3/31/17 12/31/16 Cash, cash equivalents and investments $558 $579 Principal debt outstanding Convertible senior notes (2.5%) $200 $200 Term loan facility (4.75%) 324 328 2023 senior notes (7.875%) 500 500 Total debt outstanding $1,024 $1,028 ($M) 3/31/17 12/31/16 Net

  25. Slide 25: Makena: Strong Underlying Fundamentals

    Actual ex-factory sales ($M) Estimated ex-factory sales ($M) $86.5 $100 - $105 $110 - $120 $115 - $130 Q1-2017 Q2-2017 Q3-2017 Q4-2017 Makena: Strong Underlying Fundamentals Reaffirming Makena 2017 Revenue Guidance $410 M - $440 M 25

  26. Slide 26: Updated 2017 Financial Guidance

    Updated 2017 Financial Guidance 26 ($M) 2017 GAAP Guidance 2017 Non-GAAP Guidance Previous Updated Previous1 Updated1 Makena sales $410 - $440 $410 - $440 $410 - $440 $410 - $440 Feraheme/MuGard sales $100 - $110 $100 - $110 $100 - $110 $100 - $110 CBR revenue $110 - $120 $110 - $120 $115 - $1252 $1

  27. Slide 27: AMAG Portfolio: Multiple Value Drivers

    AMAG Portfolio: Multiple Value Drivers 27 Milestone 2017 2018 MAKENA AUTO-INJECTOR PROGRAM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Topline PK data sNDA submission Expected FDA action and commercial launch FERAHEME IDA LABEL EXPANSION Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Enrollment completed Topline data sNDA submission Expected

  28. Slide 28: Key Product Launch Milestones

    Key Product Launch Milestones 28 5 Potential Product Launches over Next 4 Years Velo (severe preeclampsia) R ev e nu e Today 2017 2018 2019 2020 Makena subcutaneous auto-injector IDA (non-CKD) BREMELANOTIDE

  29. Slide 29: AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update

    AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update May 2, 2017

  30. Slide 30: Appendix

    Appendix

  31. Slide 31: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results 31 ($M) GAAP operating income (loss) Purchase accounting adjustments related to CBR deferred revenue Depreciation and intangible asset amortization Non-cash inventory step-up adjustments Stock-based compensation Adjustments to contingent considera

  32. Slide 32: Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance 2017 Financial Guidance ($M) Previous Updated GAAP net income $19 - $60 ($88) – ($44) Adjustments: Interest expense, net 71 71 Provision for income tax expense (benefit) 13 - 42 (55) – (26) Operating income (loss) $103 - $173 ($72) – $1 Purc

  33. Slide 33: Share Count Reconciliation

    Share Count Reconciliation 1 Employee equity incentive awards, convertible notes and warrants would be anti-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the convertible notes. 2 Reflects the Non-GAAP dilutive i

  34. Slide 34: AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update

    AMAG Pharmaceuticals Q1-2017 Financial Results & Corporate Update May 2, 2017

Amag Pharmaceuticals — Q1 2017 Earnings Presentation on 6ix